Revenue Growth
Overall revenue grew 21.8% in the third quarter compared to the prior year period, driven by an exceptional oral drug revenue growth of approximately 80%.
Capitation Contracts
Signed an additional 3 capitation contracts across 2 states, including the first capitation contract in Oregon.
Radiopharmaceutical Therapy Certification
Achieved certification to begin Radiopharmaceutical Therapy in California, expected to be a significant growth driver.
Cash Surplus
Cash and cash equivalents increased by $1 million compared to Q2 2024, marking the first quarterly cash surplus this year.
SG&A Expense Reduction
Generated a 6% reduction in SG&A expenses compared to the prior year, showcasing efforts to streamline operations.
Improved Gross Margin
Gross profit for Q3 2024 was $14.4 million, an increase of 10.3% compared to Q2 2024, attributed to improved IV margins.
Legal Settlement Cash Inflow
A favorable legal settlement in Q4 is expected to generate a cash inflow of $4.1 million.